Profile data is unavailable for this security.
About the company
Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). It received orphan drug designation from the European Commission for TSHA-120 for the treatment of GAN.
- Revenue in USD (TTM)14.16m
- Net income in USD-118.01m
- Incorporated2020
- Employees52.00
- LocationTaysha Gene Therapies Inc3000 Pegasus Park Drive, Suite 1430DALLAS 75247United StatesUSA
- Phone+1 (214) 612-0000
- Websitehttps://tayshagtx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ACELYRIN Inc | 0.00 | -240.16m | 410.96m | 130.00 | -- | 0.637 | -- | -- | -2.59 | -2.59 | 0.00 | 6.52 | 0.00 | -- | -- | 0.00 | -48.23 | -- | -52.78 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -489.21 | -- | -- | -- |
Grail Inc | 100.18m | -1.49bn | 411.26m | 1.36k | -- | 0.11 | -- | 4.11 | -56.16 | -56.16 | 3.77 | 140.84 | -- | -- | -- | 74,763.43 | -- | -47.45 | -- | -48.55 | 41.91 | -- | -1,488.21 | -5,118.86 | -- | -- | 0.00 | -- | 67.61 | -- | 72.85 | -- | -4.22 | -- |
Heron Therapeutics Inc | 132.10m | -80.95m | 417.31m | 126.00 | -- | -- | -- | 3.16 | -0.6156 | -0.6156 | 0.9316 | -0.2245 | 0.6021 | 1.20 | 2.26 | 1,048,405.00 | -36.90 | -53.55 | -56.71 | -71.24 | 57.08 | 52.52 | -61.28 | -170.12 | 1.90 | -- | 1.29 | -- | 17.99 | 10.40 | 39.26 | -- | -29.97 | -- |
Voyager Therapeutics Inc | 119.04m | -3.04m | 420.46m | 162.00 | -- | 1.23 | 276.98 | 3.53 | -0.1812 | -0.1812 | 2.44 | 6.28 | 0.2954 | -- | 8.27 | 734,839.50 | -0.7554 | 0.6378 | -0.8534 | 0.8203 | -- | -- | -2.56 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
Ocugen Inc | 7.05m | -58.50m | 422.06m | 65.00 | -- | 13.95 | -- | 59.87 | -0.2348 | -0.2348 | 0.028 | 0.1176 | 0.0952 | -- | -- | 108,461.50 | -79.01 | -83.56 | -100.56 | -97.79 | -- | -- | -829.84 | -2,921.94 | -- | -- | 0.0855 | -- | 142.60 | -- | 27.33 | -- | 39.08 | -- |
Alector Inc | 96.41m | -120.61m | 425.06m | 244.00 | -- | 2.38 | -- | 4.41 | -1.39 | -1.39 | 1.12 | 1.86 | 0.1393 | -- | -- | 395,106.60 | -17.43 | -20.00 | -21.55 | -23.81 | -- | -- | -125.11 | -124.07 | -- | -- | 0.00 | -- | -27.36 | 28.52 | 2.19 | -- | 4.79 | -- |
Compass Pathways PLC (ADR) | 0.00 | -129.44m | 428.75m | 186.00 | -- | 1.65 | -- | -- | -2.37 | -2.37 | 0.00 | 3.79 | 0.00 | -- | -- | 0.00 | -53.68 | -40.85 | -57.32 | -44.48 | -- | -- | -- | -- | -- | -43.34 | 0.1009 | -- | -- | -- | -29.46 | -- | -12.68 | -- |
OmniAB Inc | 21.05m | -63.48m | 429.30m | 106.00 | -- | 1.42 | -- | 20.40 | -0.634 | -0.634 | 0.2103 | 2.57 | 0.055 | -- | 7.18 | 198,547.20 | -16.58 | -- | -17.48 | -- | -- | -- | -301.63 | -- | -- | -- | 0.00 | -- | -42.17 | -- | -126.65 | -- | -- | -- |
Verve Therapeutics Inc | 16.05m | -196.83m | 431.58m | 255.00 | -- | 0.7389 | -- | 26.89 | -2.87 | -2.87 | 0.2309 | 6.96 | 0.0235 | -- | 4.48 | 62,937.25 | -28.80 | -- | -30.24 | -- | -- | -- | -1,226.43 | -- | -- | -- | 0.00 | -- | 505.77 | -- | -27.12 | -- | -- | -- |
Taysha Gene Therapies Inc | 14.16m | -118.01m | 432.97m | 52.00 | -- | 7.47 | -- | 30.59 | -1.19 | -1.19 | 0.0896 | 0.2879 | 0.1112 | -- | -- | 272,230.80 | -92.70 | -- | -146.13 | -- | -- | -- | -833.60 | -- | -- | -- | 0.4315 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
Allogene Therapeutics Inc | 87.00k | -292.30m | 433.44m | 232.00 | -- | 0.7685 | -- | 4,982.05 | -1.78 | -1.78 | 0.0005 | 2.71 | 0.0001 | -- | -- | 375.00 | -43.85 | -28.46 | -47.04 | -30.21 | -- | -- | -335,973.60 | -1,123.44 | -- | -- | 0.00 | -- | -39.10 | -- | 3.86 | -- | -14.06 | -- |
Terns Pharmaceuticals Inc | 0.00 | -91.06m | 443.69m | 66.00 | -- | 1.87 | -- | -- | -1.26 | -1.26 | 0.00 | 3.66 | 0.00 | -- | -- | 0.00 | -33.23 | -41.34 | -34.55 | -45.70 | -- | -- | -- | -31,010.30 | -- | -- | 0.00 | -- | -- | -- | -49.49 | -- | -26.60 | -- |
Lenz Therapeutics Inc | 0.00 | -117.37m | 450.94m | 6.00 | -- | 2.27 | -- | -- | -15.88 | -15.88 | 0.00 | 7.77 | 0.00 | -- | -- | 0.00 | -44.51 | -- | -47.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.35 | -- | -- | -- |
Exscientia PLC (ADR) | 24.98m | -164.76m | 465.67m | 483.00 | -- | 1.61 | -- | 18.64 | -1.30 | -1.30 | 0.1977 | 3.33 | 0.0364 | -- | 34.98 | 51,719.61 | -24.02 | -- | -27.31 | -- | -34.40 | -- | -659.56 | -- | -- | -- | 0.0556 | -- | -26.24 | -- | -22.94 | -- | -- | -- |
Neurogene Inc | 0.00 | -39.03m | 467.03m | 91.00 | -- | 2.71 | -- | -- | -4.58 | -4.58 | 0.00 | 13.28 | 0.00 | -- | -- | 0.00 | -26.57 | -32.70 | -28.41 | -34.73 | -- | -- | -- | -- | -- | -- | 0.0006 | -- | -- | -- | 36.90 | -- | 45.63 | -- |
Altimmune Inc | 410.00k | -92.77m | 467.95m | 59.00 | -- | 2.71 | -- | 1,141.35 | -1.59 | -1.59 | 0.007 | 2.44 | 0.0022 | -- | 1.47 | 6,949.15 | -49.42 | -39.62 | -53.14 | -42.58 | -- | -- | -22,626.10 | -1,811.89 | -- | -- | 0.00 | -- | 726.47 | -47.15 | -4.41 | -- | -45.92 | -- |
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 20.11m | 10.75% |
Avoro Capital Advisor LLCas of 31 Mar 2024 | 18.65m | 9.97% |
RTW Investments LPas of 31 Mar 2024 | 18.59m | 9.94% |
RA Capital Management LPas of 31 Mar 2024 | 10.87m | 5.81% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 5.88m | 3.14% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 5.01m | 2.68% |
Baker Bros. Advisors LPas of 31 Mar 2024 | 4.00m | 2.14% |
Tybourne Capital Management (HK) Ltd.as of 31 Mar 2024 | 3.70m | 1.98% |
Invus Public Equities Advisors LLCas of 31 Mar 2024 | 3.69m | 1.97% |
Acuta Capital Partners LLCas of 31 Mar 2024 | 3.33m | 1.78% |